Lung
GRACE
From Bench to Bedside: Genomic Discoveries Driving Lung Cancer Therapies
FEATURING
Triparna Sen
- April 17, 2025
GRACE
Reading a Molecular Testing Report in Lung Cancer
FEATURING
Karen Yun
- 35 views
- April 1, 2025
- 1
GRACE
ALK, ROS1, and RET in NSCLC: Pushing the Boundaries of Targeted Therapies
FEATURING
Christine Bestvina
- 40 views
- April 1, 2025
- 1
GRACE
EGFR and HER2 Targeted Therapies in NSCLC: New Developments and a Changing Landscape
FEATURING
Xiuning Le
- 30 views
- April 1, 2025
GRACE
Patient Selection Strategies for Optimal Metastatic NSCLC Treatment
FEATURING
Puneeth Lyengar
- 13 views
- March 27, 2025
GRACE
LCT for Limited Metastatic NSCLC: NRG-LU002 Limitations & Summary
FEATURING
Puneeth Lyengar
- 2 views
- March 27, 2025
GRACE
LCT for Limited Metastatic NSCLC: NRG-LU002 Results
FEATURING
Puneeth Lyengar
- 1 view
- March 27, 2025
GRACE
Integrating Local Therapy in Metastatic NSCLC: Consolidation Focus
FEATURING
Puneeth Lyengar
- 1 view
- March 27, 2025
GRACE
Considerations for Local Treatment in Metastatic NSCLC
FEATURING
Puneeth Lyengar
- 1 view
- March 27, 2025
GRACE
Using Tarlatamab for Extensive Stage SCLC
FEATURING
Aakash Desai,
Fawzi Abu Rous
- 84 views
- December 1, 2024
- 1
GRACE
Advancing Treatment in EGFR-Mutated NSCLC: Results From MARIPOSA2 and LAURA Trials
FEATURING
Aakash Desai,
Fawzi Abu Rous
- 78 views
- December 1, 2024
GRACE
Advancing Treatment in EGFR-Mutated NSCLC: Results From FLAURA2 and MARIPOSA Trials
FEATURING
Aakash Desai,
Fawzi Abu Rous
- 153 views
- December 1, 2024
- 1
GRACE
Case-Based Panel: Managing EGFR Exon 21 L858R mNSCLC and Insights From the FLAURA 2 Study
- 52 views
- November 5, 2024
GRACE
Case-Based Panel: Treating 70 y/o Female With SCLC and Insights From the ADRIATIC Study
- 143 views
- November 5, 2024
- 2
GRACE
Case-Based Panel: Managing EGFR Exon 19 Lung Cancer and Insights From the LAURA Study
- 78 views
- November 5, 2024
GRACE
An Overview of KRAS+ NSCLC and Diagnostic Testing
FEATURING
Jia Luo
- 127 views
- September 12, 2024
- 2
GRACE
Targeted Therapy in Lung Cancer: Side Effects
FEATURING
Tejas Patil
- 110 views
- September 12, 2024
GRACE
Targeted Therapy in Lung Cancer: The Importance of Biomarkers
FEATURING
Tejas Patil
- 123 views
- September 12, 2024
- 1
GRACE
Lung Resection in Early Stage NSCLC: An Overview
FEATURING
Chi-Fun Jeffrey Yang
- 267 views
- May 15, 2024
- 1
GRACE
Using Radiation to Improve Outcomes and QoL in Patients With mNSCLC
FEATURING
Puneeth Iyengar
- 11 views
- May 15, 2024
GRACE
Antibody Drug Conjugates and How They Are Used in NSCLC
FEATURING
Lyudmila Bazhenova
- 34 views
- May 1, 2024
GRACE
Amivantamab in 1L Advanced NSCLC With EGFR exon 20 Insertion Mutations
FEATURING
Lyudmila Bazhenova
- 41 views
- May 1, 2024
GRACE
Treatment Options for EGFR+ NSCLC
FEATURING
Ibiayi Dagogo-Jack,
Natalie Vokes
- 34 views
- June 26, 2023
GRACE
Surgical Options for Stage IV NSCLC With Brain Metastases: 60 y/o Woman With Headache, Nausea, and Gait Imbalance
FEATURING
Ibiayi Dagogo-Jack,
Joshua Reuss
- 18 views
- June 26, 2023
GRACE
Neoadjuvant Chemo +/- Nivo for Patients With Early Stage NSCLC: Case-Based Panel Discussion
FEATURING
Ibiayi Dagogo-Jack,
Joshua Reuss
- 91 views
- May 9, 2023
GRACE
Treating Stage III NSCLC: Case-Based Panel Discussion
FEATURING
Ibiayi Dagogo-Jack,
Kathryn Arbour
- 22 views
- May 9, 2023
GRACE
Neoadjuvant Therapy vs. Adjuvant Therapy in NSCLC: What Is the Future Role?
- 106 views
- June 3, 2022
- 1
GRACE
Testing in Potentially Resectable & Unresectable Locally Advanced NSCLC
- 100 views
- June 3, 2022
- 1
GRACE
The Need for Broad Molecular Testing for Driver Mutations in NSCLC
FEATURING
Justin Gainor
- 108 views
- May 23, 2021
GRACE
NSCLC Frontline Therapy for Uncommon Mutations: Overview of RET, NTRK, MET & BRAF & Available Agents
FEATURING
Justin Gainor
- 110 views
- May 20, 2021
GRACE
Expert Discussion on Targeted Therapy for mNSCLC: Can ALK Inhibitors Treat and Prevent Brain Mets?
FEATURING
Jack West
- 40 views
- March 31, 2021
GRACE
Targeted Therapy for EGFR+ NSCLC: How Do We Think About Acquired Resistance? How to Assess for Osimertinib Resistance?
FEATURING
Zofia Piotrowska
- 115 views
- March 1, 2021
- 1
GRACE
Targeted Therapy for EGFR+ NSCLC: What Are the Current Options Upon Acquired Resistance to Osimertinib?
FEATURING
Zofia Piotrowska
- 105 views
- March 1, 2021
- 1
GRACE
2020 ASCO Update on Advanced NSCLC: What Is the Role for Nivolumab/Ipilimumab Combination Today?
- 131 views
- November 30, 2020
GRACE
2020 ASCO Update on MET/RET+ NSCLC: How Promising Are Capmatinib & Pralsetinib?
- 126 views
- November 30, 2020
- 1
GRACE
2020 ASCO Update on HER2+ NSCLC: Is There a Promising Clinical Activity With T-DXd?
- 20 views
- November 30, 2020
GRACE
ASCO 2020 Updates on PD-L1 NSCLC: Is Tiragolumab+Atezo Beneficial for ORR/PFS vs. Atezo+Placebo?
- 79 views
- November 27, 2020
GRACE
SCLC Updates: What Are the Leading Immunotherapy Options?
FEATURING
Stephen Liu
- 315 views
- October 30, 2020
- 3
GRACE
Expert Discussion on mNSCLC: What Are the Leading Treatment Options for Patients With Negative Tumor PD-L1?
FEATURING
Stephen Liu
- 342 views
- October 30, 2020
- 3
GRACE
2020 Update on Molecular Abnormalities in NSCLC: How Do MET Exon 14 Skipping Mutations Work? Is Capmatinib Better Performing Than Crizotinib?
FEATURING
Joshua Bauml
- 251 views
- September 30, 2020
- 3
GRACE
The Role of IO for NSCLC Patients With Driver Mutations: What Data Do We Have?
FEATURING
Benjamin Levy
- 197 views
- September 30, 2020
- 2
GRACE
Does Immunotherapy Have Activity in Malignant Pleural Mesothelioma?
FEATURING
Millie Das
- 212 views
- June 9, 2020
- 2
GRACE
Non-Small Cell Lung Cancer: What Are the Recommended Treatments for Common EGFR Mutations?
- 127 views
- May 21, 2020
GRACE
The Challenges of Potential Pneumonitis Following Durvalumab in Stage 3 NSCLC
- 21 views
- March 13, 2020
GRACE
Unresectable NSCLC: What Is TMB and Does it Add Significant Benefit to Guide Treatment Recommendations?
- 479 views
- March 12, 2020
- 2
GRACE
Should Molecular Tests Be Considered in Stage 3 NSCLC and Would Outcome Effect Treatment Decisions?
- 324 views
- March 12, 2020
- 2
GRACE
Case of 60 y/o Woman with ALK Positive Metastatic NSCLC: Approach to 1st Line Treatment
- 200 views
- March 13, 2020
GRACE
Treatment for NSCLC Patient Who Developed Resistance to ALK Inhibitors
- 21 views
- March 13, 2020
GRACE
Is the Standard Treatment the Best Approach for Stage 3 Frail Patient with Unresectable NSCLC?
- 399 views
- March 13, 2020
- 1
GRACE
Case Based Discussion on Stage 3 NSCLC: Should We Do Molecular Tests and Would That Effect the Treatment Decision?
- 353 views
- January 29, 2020
- 2
GRACE
CancerGRACE's ASCO 2019 Update on Lung Cancer: How Promising is Lurbinectedin for Relapsed SCLC?
- 880 views
- September 24, 2019
- 3
GRACE
CancerGRACE's ASCO 2019 Update on Lung Cancer: Short Discussion on KRAS G12C as a Target
- 179 views
- September 24, 2019
GRACE
CancerGRACE's ASCO 2019 Update on Lung Cancer: Circulating Tumor DNA for Monitoring Disease Status
- 100 views
- September 24, 2019
GRACE
CancerGRACE's ASCO 2019 Update on Lung Cancer: Retrospective Analysis of STK11 and KEAP Targets
- 102 views
- September 24, 2019
GRACE
CancerGRACE's ASCO 2019 Update on Stage IV NSCLC: New Targets - RET
- 150 views
- September 24, 2019
- 1
GRACE
CancerGRACE's ASCO 2019 Highlights and New Approaches in Stage IV NSCLC: Long Term Outcomes with Pembrolizumab
- 287 views
- September 24, 2019
- 2
GRACE
CancerGRACE's ASCO 2019 Highlights and New Approaches in Stage IV NSCLC: New Targets - MET
- 70 views
- September 24, 2019
GRACE
CancerGRACE's 2019 ASCO Highlights in Advanced NSCLC: What is the Long-Term Survival Benefit With Pembrolizumab?
- 225 views
- September 6, 2019
- 1
GRACE
CancerGRACE's 2019 ASCO Highlights on Adjuvant Afatinib in Stage II and III EGFR+ NSCLC - What Have We Learned?
- 471 views
- September 6, 2019
- 3
GRACE
CancerGRACE's 2019 ASCO Highlights on Stage I NSCLC Adjuvant Chemotherapy - Retrospective Japanese Data
- 27 views
- September 6, 2019
GRACE
Is There a Role for IO in EGFR+ Metastatic Lung Cancer?
FEATURING
Helena Yu
- 4,793 views
- August 2, 2019
- 29
GRACE
Initial Treatment and Acquired Resistance in Advanced Lung Cancer & Targeting BRAF, RET, and BRAF
FEATURING
Joshua Bauml,
Joshua K. Sabari
- 209 views
- August 2, 2019
- 1
GRACE
Q&A on Targeted Therapies in Advanced Lung Cancer
FEATURING
Joshua Bauml
- 16 views
- August 2, 2019
GRACE
Introduction to Next Generation Sequencing in Metastatic Lung Cancer: Current Status, Barriers and Emerging Targets
FEATURING
Joshua Bauml
- 633 views
- August 2, 2019
- 2
GRACE
EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC
FEATURING
Helena Yu
- 179 views
- July 22, 2019
- 1
GRACE
Q&A on EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC
FEATURING
Helena Yu
- 34 views
- July 22, 2019
- 1
GRACE
Optimal First Line Treatment of EGFR+ Advanced NSCLC: First and Second Generation EGFR TKIs
FEATURING
Jack West
- 115 views
- July 22, 2019
GRACE
Optimal First Line Treatment of EGFR+ Advanced NSCLC: Osimertinib vs. Standard of Care EGFR TKIs and Chemo
FEATURING
Jack West
- 565 views
- July 22, 2019
- 2
GRACE
Optimal First Line Treatment of EGFR+ Advanced NSCLC: Dacomitinib, Erlotinib vs Bevacizumab, Gefitinib+Chemo
FEATURING
Jack West
- 679 views
- July 22, 2019
- 2
GRACE
Targeted Therapies in Advanced Lung Cancer: What is the Role of Rebiopsy?
FEATURING
Hossein Borghaei
- 464 views
- July 22, 2019
- 3
GRACE
Discussion/Q&A on Targeted Therapies in Advanced Lung Cancer
FEATURING
Hossein Borghaei
- 25 views
- July 22, 2019
GRACE
Targeted Therapies in Metastatic NSCLC: Liquid Biopsies as a New Option in Patient Care and Day-to-Day Management
FEATURING
Charu Aggarwal
- 623 views
- July 22, 2019
- 3
GRACE
Immunotherapy in Stage lll NSCLC - The Pacific Trial and Imfinzi
FEATURING
Karen Kelly
- 172 views
- January 17, 2019
GRACE
Tumor Mutation Burden in Patients with Non-Squamous NSCLC: Current Status
FEATURING
Sandip Patel
- 25 views
- January 17, 2019
GRACE
Evolving Standards for Molecular Testing in Advanced NSCLC
FEATURING
Sandip Patel
- 25 views
- January 17, 2019
GRACE
Combinations of Immunotherapy Agents in Advanced NSCLC: Current Status
FEATURING
Sandip Patel
- 20 views
- January 17, 2019
GRACE
The Basics of Managing Immune-Mediated Side Effects in NSCLC
FEATURING
Sandip Patel
- 29 views
- January 17, 2019
GRACE
What Should Patients With Rapid Progression in Advanced NSCLC Through 1st Line Treatment Receive Next?
FEATURING
Jack West
- 193 views
- January 17, 2019
GRACE
"Consolidation" Radiation After a Good Response to First Line Therapy in Advanced and Metastatic NSCLC - Who and Why?
FEATURING
Jack West
- 16 views
- January 17, 2019
GRACE
Chemotherapy and Immunotherapy Combinations in Advanced Non-Squamous NSCLC
FEATURING
Jack West
- 167 views
- January 17, 2019
GRACE
Chemo Immuno Therapy Combinations in Advanced Squamous NSCLC
FEATURING
Jack West
- 182 views
- January 17, 2019
- 1
GRACE
Does Immunotherapy Work in Patients with Driver Mutations Like EGFR and ALK in Advanced NSCLC?
FEATURING
Jack West
- 238 views
- January 17, 2019
GRACE
EGFR TKI Gilotrif(Afatinib) in Metastatic Squamous NSCLC
FEATURING
Vamsidhar Velcheti
- 202 views
- January 17, 2019
- 1
GRACE
Lung Cancer Immunotherapy- Is There Anything Better than PDL1
FEATURING
Vamsidhar Velcheti
- 116 views
- January 17, 2019
GRACE
The Changing Landscape of 1L Treatment of ALK-Positive Advanced NSCLC: What Does the ALEX Data Show?
FEATURING
Alice Shaw
- 46 views
- January 17, 2019
GRACE
Patterns of Resistance in ALK Positive NSCLC
FEATURING
Alice Shaw
- 229 views
- January 17, 2019
- 1
GRACE
Controlling Brain Metastases in Patients with Molecular Driven Advanced NSCLC
FEATURING
Alice Shaw
- 34 views
- January 17, 2019
GRACE
Immunotherapy for Previously Treated Patients with NSCLC
FEATURING
Karen Reckamp
- 17 views
- January 17, 2019
GRACE
New Options in Acquired Resistance for ALK+ Metastatic Non-small Cell Lung Cancer (NSCLC)
FEATURING
Nathan Pennell
- 237 views
- January 17, 2019
GRACE
The Role for Immunotherapy in Patients with a Driver Mutation Lung Cancer
FEATURING
Nathan Pennell
- 20 views
- January 17, 2019
GRACE
Liquid Biopsies for Broad Genomic Testing in Lung Cancer
FEATURING
Nathan Pennell
- 36 views
- January 17, 2019
GRACE
Liquid Biopsies for EGFR T790M Advanced NSCLC
FEATURING
Nathan Pennell
- 21 views
- January 17, 2019
GRACE
The Role of Angiogenesis in Previously Treated NSCLC
FEATURING
Karen Reckamp
- 21 views
- January 29, 2019
GRACE
Advanced Non Squamous NSCLC, High PD-L1, No Mutation - Optimal 1st Line? - Case Based Panel Discussion
- 220 views
- January 29, 2019
GRACE
Advanced Non Squamous NSCLC, Low PD-L1, No Mutation - Best Systemic Therapy? - Case Based Panel Discussion
- 237 views
- January 29, 2019
GRACE
Case Based Panel Discussion - Fit Patient Adv Squamous NSCLC Low Tumor PD-L1
- 16 views
- January 29, 2019
GRACE
Lung Cancer Case Based Panel Discussion - EGFR and High PDL-1, Choosing Targeted Therapy or Immunotherapy
- 151 views
- January 29, 2019
- 1
GRACE
Case Based Panel Discussions - Metastatic Squamous NSCLC Low Tumor PD-L1 Frail Patient - Treatment?
- 17 views
- January 29, 2019
GRACE
Rapid Progression Lung Adenocarcinoma High PD-L1 - How Do You Treat? Case Based Panel Discussion
- 71 views
- January 29, 2019
GRACE
ASCO 2018 - Keynote 042 - Keytruda as a Single Agent Compared to Doublet Chemotherapy for NSCLC
- 356 views
- January 29, 2019
GRACE
ASCO 2018 - Potential Showdown of Two Positive Trials? Keynote 407 and IMPower 131
- 24 views
- January 29, 2019
GRACE
ASCO 2018 Keynote189 - Cisplatin or Carboplatin with Alimta & Keytruda - Practice Changing Approach?
- 22 views
- January 29, 2019
GRACE
ASCO 2018 - Checkmate 227 - Combinations of Nivolumab and Ipilimumab, or Nivolumab and Chemo
- 25 views
- January 29, 2019
GRACE
ASCO 2018 - Will Taking Mod to High Dose Steroids Affect Lung Cancer Pts on Immunotherapy?
- 15 views
- January 29, 2019
GRACE
ASCO 2018 - Tarceva or Tarceva with Avastin as 1st Line for EGFR Pos. NSCLC vs. Tagrisso or Vizimpro
- 16 views
- January 29, 2019
GRACE
ASCO 2018 - Tarceva Combined with Carboplatin & Alimta - Given Upfront - Affect Pace of Disease?
- 19 views
- January 29, 2019
GRACE
ASCO 2018 - Combining Metformin with Standard EGFR Therapy - Is the Jury Still Out
- 23 views
- January 29, 2019
GRACE
ASCO 2018 - Keynote 158 - Keytruda in Previously Treated, Now Relapsing Patients with SCLC
- 19 views
- January 29, 2019
GRACE
ASCO 2018 - Dream Study - Chemo with Imfinzi (durvalumab) for Mesothelioma
- 32 views
- January 29, 2019
GRACE
OncTalk 2018 - Newer Technologies in Radiation - Local Therapies for Metastatic Lung Cancer
FEATURING
Vivek Mehta
- 21 views
- January 30, 2019
GRACE
OncTalk 2018 - Novel Indications for Local Therapy in Adv NSCLC - Local Therapies for Metastatic LC
FEATURING
Puneeth Iyengar
- 9 views
- January 30, 2019
GRACE
OncTalk 2018 - Systemic Therapies for Advanced NSCLC - Local Therapies for Metastatic LC
FEATURING
Jack West
- 23 views
- January 30, 2019
GRACE
OncTalk 2018 - Panel Discussion and Q&A - Local Therapies for Metastatic LC
- 16 views
- January 30, 2019